Dishman Carbogen Amcis Limited Asset Resilience Ratio
Dishman Carbogen Amcis Limited asset resilience ratio. Dishman Carbogen Amcis Limited (DCAL) has an Asset Resilience Ratio of 5.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DCAL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dishman Carbogen Amcis Limited (2005–2025)
Asset resilience ratio of Dishman Carbogen Amcis Limited from 2005 to 2025. This chart shows how Dishman Carbogen Amcis Limited's Asset Resilience Ratio has changed over time. Read Dishman Carbogen Amcis Limited (DCAL) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dishman Carbogen Amcis Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Dishman Carbogen Amcis Limited total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs6.16 Billion | 5.54% |
| Short-term Investments | Rs157.30 Million | 0.14% |
| Total Liquid Assets | Rs6.31 Billion | 5.68% |
Asset Resilience Insights
- Limited Liquidity: Dishman Carbogen Amcis Limited maintains only 5.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dishman Carbogen Amcis Limited Industry Peers by Asset Resilience Ratio
Compare Dishman Carbogen Amcis Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Dishman Carbogen Amcis Limited Asset Resilience Ratio by Year (2005–2025)
Dishman Carbogen Amcis Limited asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Dishman Carbogen Amcis Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.35% | Rs354.30 Million ≈ $3.83 Million |
Rs99.99 Billion ≈ $1.08 Billion |
-1.42pp |
| 2024-03-31 | 1.77% | Rs1.70 Billion ≈ $18.38 Million |
Rs95.81 Billion ≈ $1.04 Billion |
-0.62pp |
| 2023-03-31 | 2.40% | Rs2.26 Billion ≈ $24.49 Million |
Rs94.53 Billion ≈ $1.02 Billion |
-1.59pp |
| 2022-03-31 | 3.98% | Rs3.44 Billion ≈ $37.22 Million |
Rs86.37 Billion ≈ $934.11 Million |
+1.74pp |
| 2021-03-31 | 2.24% | Rs1.88 Billion ≈ $20.29 Million |
Rs83.66 Billion ≈ $904.76 Million |
+0.60pp |
| 2020-03-31 | 1.64% | Rs1.35 Billion ≈ $14.57 Million |
Rs82.00 Billion ≈ $886.78 Million |
+1.00pp |
| 2019-03-31 | 0.64% | Rs471.10 Million ≈ $5.09 Million |
Rs73.28 Billion ≈ $792.55 Million |
-1.08pp |
| 2018-03-31 | 1.73% | Rs1.24 Billion ≈ $13.40 Million |
Rs71.76 Billion ≈ $776.11 Million |
+1.42pp |
| 2017-03-31 | 0.30% | Rs199.20 Million ≈ $2.15 Million |
Rs65.93 Billion ≈ $713.05 Million |
+0.18pp |
| 2016-03-31 | 0.12% | Rs36.30 Million ≈ $392.57K |
Rs29.81 Billion ≈ $322.33 Million |
-0.35pp |
| 2015-03-31 | 0.47% | Rs132.00 Million ≈ $1.43 Million |
Rs28.13 Billion ≈ $304.22 Million |
+0.47pp |
| 2013-03-31 | 0.00% | Rs117.00K ≈ $1.27K |
Rs23.15 Billion ≈ $250.35 Million |
-0.20pp |
| 2012-03-31 | 0.21% | Rs46.13 Million ≈ $498.86K |
Rs22.49 Billion ≈ $243.22 Million |
-0.07pp |
| 2011-03-31 | 0.27% | Rs56.35 Million ≈ $609.41K |
Rs20.82 Billion ≈ $225.19 Million |
+0.27pp |
| 2008-03-31 | 0.00% | Rs-1.00K ≈ $-10.81 |
Rs14.70 Billion ≈ $158.94 Million |
-0.36pp |
| 2005-03-31 | 0.36% | Rs11.65 Million ≈ $126.00K |
Rs3.22 Billion ≈ $34.84 Million |
-- |
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more